Search
Ibrigampar
go.drugbank.com/drugs/DB05490InvestigationalT131 is a selective modulator of PPARg (peroxisome proliferator activated receptor gamma), a receptor involved in regulating the body’s ability to respond to insulin.
ATN-161
go.drugbank.com/drugs/DB05491Investigationalexpected to extend to a variety of cancers. … ATN-161 is a non-RGD based integrin binding peptide targeting alpha-5 beta-1 and alpha-v beta-3.
LI-301
go.drugbank.com/drugs/DB05509ExperimentalIt has a novel mode of action combining both the light effect of a Selective Serotonin Reuptake Inhibitor ("SSRI")(most likely antagonistic at 5HT1a receptors) and antagonism at mu-opioid receptors. … LI 301 is an orally bio-available compound delivered in a fast melt mechanism with taste masking enabling it to be taken anytime without water.
AVI-4065
go.drugbank.com/drugs/DB05620InvestigationalAVI-4065, a phosphorodiamidate Morpholino oligomer (PMO), is an investigational antisense HCV drug. It was developed by Sarepta Therapeutics, Inc.
AC-100
go.drugbank.com/drugs/DB05671InvestigationalAC-100 is a novel synthetic peptide derived from an endogenous human protein produced by bone and dental cells (a fragment from matrix extracellular phosphoglycoprotein).
GTS-21
go.drugbank.com/drugs/DB05708InvestigationalGTS-21 (also known as DMBX-A), is a novel, small-molecule, orally active and selective alpha-7 nicotinic acetylcholine (nACh) receptor agonist that has demonstrated memory and cognition enhancement activity … In a Phase I multi-dose, double-blind, placebo controlled study in healthy adults, GTS-21 also demonstrated cognitive enhancement across all doses, with a statistically significant improvement in attention
Synonyms: DMXB-AElesclomol
go.drugbank.com/drugs/DB05719InvestigationalElesclomol is a novel, injectable, drug candidate that kills cancer cells by elevating oxidative stress levels beyond a breaking point, triggering programmed cell death. … In preclinical models elesclomol showed potent killing of a broad range of cancer cell types at high doses, and an ability to strongly enhance the efficacy of certain chemotherapy agents, with minimal
CYT006-AngQb
go.drugbank.com/drugs/DB05739InvestigationalCYT006-AngQb is a therapeutic vaccine in development for treatment of hypertension. … It is a unique treatment modality that aims to address the issue of patient compliance by offering convenient dosing schedules due to the long-lasting effect induced by vaccination.
Drinabant
go.drugbank.com/drugs/DB05750InvestigationalAVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant. It is currently developed in obesity and its associated comorbidities. AVE-1625 is also being develop...
PAC-113
go.drugbank.com/drugs/DB05756InvestigationalIt is a 12 amino-acid antimicrobial peptide derived from a naturally occurring histatin protein found in saliva.